You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Vismodegib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for vismodegib and what is the scope of patent protection?

Vismodegib is the generic ingredient in one branded drug marketed by Genentech and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vismodegib has fifty-three patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for vismodegib
International Patents:53
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 127
Clinical Trials: 77
Patent Applications: 3,554
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in vismodegib?vismodegib excipients list
DailyMed Link:vismodegib at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vismodegib
Generic Entry Date for vismodegib*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vismodegib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sun Pharmaceutical Industries LimitedPhase 2
H. Lee Moffitt Cancer Center and Research InstituteEarly Phase 1
Genentech, Inc.Early Phase 1

See all vismodegib clinical trials

Pharmacology for vismodegib

US Patents and Regulatory Information for vismodegib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for vismodegib

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Roche Registration GmbH Erivedge vismodegib EMEA/H/C/002602
Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Authorised no no no 2013-07-12 2013-04-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for vismodegib

Country Patent Number Title Estimated Expiration
Japan 2012184255 HEDGEHOG SIGNAL TRANSDUCTION PYRIDYL INHIBITOR ⤷  Try a Trial
Spain 2377430 ⤷  Try a Trial
Norway 339260 ⤷  Try a Trial
Israel 181673 תרכובות פירידילים מעכבים איתות במסלול hedgehog, תכשירים רוקחיים המכילים אותם, תהליך להכנתם ושימוש בהם להכנת תרופה לטיפול בסרטן (Pyridyl inhibitors of hedgehog signalling compounds, compositions comprising them, process for their preparation and use of said compounds for the manufacture of medicaments for treatment of cancer in a mammal) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for vismodegib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1789390 C20130027 00083 Estonia ⤷  Try a Trial PRODUCT NAME: VISMODEGIIB;REG NO/DATE: K(2013)4550 (LOPLIK) 12.07.2013
1789390 92278 Luxembourg ⤷  Try a Trial PRODUCT NAME: VISMODEGIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ERIVEDGE ); AUTHORISATION NUMBER AND DATE: 62497
1789390 122013000074 Germany ⤷  Try a Trial PRODUCT NAME: ERIVEDGE - VISMODEGIB; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: SCHWEIZ IKS-NR. 62497 20130530
1789390 CA 2013 00050 Denmark ⤷  Try a Trial PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.